154 related articles for article (PubMed ID: 37313811)
21. BAP1 antagonizes WWP1-mediated transcription factor KLF5 ubiquitination and inhibits autophagy to promote melanoma progression.
Jia X; Chen H; Ren Y; Dejizhuoga ; Gesangyuzhen ; Gao N; Feng H; Huang W; Liao Y; Yu H
Exp Cell Res; 2021 May; 402(1):112506. PubMed ID: 33516665
[TBL] [Abstract][Full Text] [Related]
22. Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients.
Cebulla CM; Binkley EM; Pilarski R; Massengill JB; Rai K; Liebner DA; Marino MJ; Singh AD; Abdel-Rahman MH
Ophthalmic Genet; 2015 Jun; 36(2):126-31. PubMed ID: 25687217
[TBL] [Abstract][Full Text] [Related]
23. Melanoma Ex Blue Nevus With GNA11 Mutation and BAP1 Loss: Case Report and Review of the Literature.
Chang LW; Kazlouskaya V; Kazi R; Davar D; Ferris RL; Ho J; Karunamurthy A; Jedrych JJ; Bunimovich YL
Am J Dermatopathol; 2020 Nov; 42(11):854-857. PubMed ID: 32310862
[TBL] [Abstract][Full Text] [Related]
24. Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome.
Marušić Z; Buljan M; Busam KJ
J Cutan Pathol; 2015 Jun; 42(6):406-12. PubMed ID: 25902915
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
Rathkey D; Khanal M; Murai J; Zhang J; Sengupta M; Jiang Q; Morrow B; Evans CN; Chari R; Fetsch P; Chung HJ; Xi L; Roth M; Filie A; Raffeld M; Thomas A; Pommier Y; Hassan R
J Thorac Oncol; 2020 May; 15(5):843-859. PubMed ID: 32004714
[TBL] [Abstract][Full Text] [Related]
26. A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers.
Aoude LG; Wadt K; Bojesen A; Crüger D; Borg A; Trent JM; Brown KM; Gerdes AM; Jönsson G; Hayward NK
PLoS One; 2013; 8(8):e72144. PubMed ID: 23977234
[TBL] [Abstract][Full Text] [Related]
27. Ambiguous melanocytic tumors with loss of 3p21.
Yeh I; Mully TW; Wiesner T; Vemula SS; Mirza SA; Sparatta AJ; McCalmont TH; Bastian BC; LeBoit PE
Am J Surg Pathol; 2014 Aug; 38(8):1088-95. PubMed ID: 24705312
[TBL] [Abstract][Full Text] [Related]
28. Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.
Kadariya Y; Cheung M; Xu J; Pei J; Sementino E; Menges CW; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
Cancer Res; 2016 May; 76(9):2836-44. PubMed ID: 26896281
[TBL] [Abstract][Full Text] [Related]
29. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.
Saha MN; Jiang H; Yang Y; Zhu X; Wang X; Schimmer AD; Qiu L; Chang H
PLoS One; 2012; 7(1):e30215. PubMed ID: 22276160
[TBL] [Abstract][Full Text] [Related]
30. Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society.
Yélamos O; Navarrete-Dechent C; Marchetti MA; Rogers T; Apalla Z; Bahadoran P; Blázquez-Sánchez N; Busam K; Carrera C; Dusza SW; de la Fouchardière A; Ferrara G; Gerami P; Kittler H; Lallas A; Malvehy J; Millán-Cayetano JF; Nelson KC; Quan VL; Puig S; Stevens H; Thomas L; Marghoob AA
J Am Acad Dermatol; 2019 Jun; 80(6):1585-1593. PubMed ID: 30244062
[TBL] [Abstract][Full Text] [Related]
31. BRCA1-associated protein (BAP1)-inactivated melanocytic tumors.
Zhang AJ; Rush PS; Tsao H; Duncan LM
J Cutan Pathol; 2019 Dec; 46(12):965-972. PubMed ID: 31233225
[TBL] [Abstract][Full Text] [Related]
32. BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells.
Pan H; Jia R; Zhang L; Xu S; Wu Q; Song X; Zhang H; Ge S; Xu XL; Fan X
Int J Biochem Cell Biol; 2015 Mar; 60():176-84. PubMed ID: 25582751
[TBL] [Abstract][Full Text] [Related]
33. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.
Ewens KG; Kanetsky PA; Richards-Yutz J; Purrazzella J; Shields CL; Ganguly T; Ganguly A
Invest Ophthalmol Vis Sci; 2014 Jun; 55(8):5160-7. PubMed ID: 24970262
[TBL] [Abstract][Full Text] [Related]
34.
Guazzelli A; Meysami P; Bakker E; Demonacos C; Giordano A; Krstic-Demonacos M; Mutti L
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669483
[TBL] [Abstract][Full Text] [Related]
35. Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations.
Gupta MP; Lane AM; DeAngelis MM; Mayne K; Crabtree M; Gragoudas ES; Kim IK
JAMA Ophthalmol; 2015 Aug; 133(8):881-7. PubMed ID: 25974357
[TBL] [Abstract][Full Text] [Related]
36. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.
Haugh AM; Njauw CN; Bubley JA; Verzì AE; Zhang B; Kudalkar E; VandenBoom T; Walton K; Swick BL; Kumar R; Rana HQ; Cochrane S; McCormick SR; Shea CR; Tsao H; Gerami P
JAMA Dermatol; 2017 Oct; 153(10):999-1006. PubMed ID: 28793149
[TBL] [Abstract][Full Text] [Related]
37. Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer.
Wang XY; Wang Z; Huang JB; Ren XD; Ye D; Zhu WW; Qin LX
Tumour Biol; 2017 Jun; 39(6):1010428317699111. PubMed ID: 28618948
[TBL] [Abstract][Full Text] [Related]
38. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
39. RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
Surget S; Descamps G; Brosseau C; Normant V; Maïga S; Gomez-Bougie P; Gouy-Colin N; Godon C; Béné MC; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
BMC Cancer; 2014 Jun; 14():437. PubMed ID: 24927749
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma.
Koopmans AE; Verdijk RM; Brouwer RW; van den Bosch TP; van den Berg MM; Vaarwater J; Kockx CE; Paridaens D; Naus NC; Nellist M; van IJcken WF; Kiliç E; de Klein A
Mod Pathol; 2014 Oct; 27(10):1321-30. PubMed ID: 24633195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
